Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Forecast Ownership Financials Chart Transcripts

Previous Close

$13.91

52W Range

$4.80 - $18.61

50D Avg

$15.24

200D Avg

$13.94

Market Cap

$1.21B

Avg Vol (3M)

$1.16M

Beta

-0.16

Div Yield

AMLX Company Profile

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

123

IPO Date

Jan 07, 2022

Website

AMLX Performance

AMLX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$87.37M	$380.79M
Operating Income	$-153.29M	$-314.73M	$38.80M
Net Income	$-144.74M	$-301.74M	$49.27M
EBITDA	$-144.16M	$-290.98M	$39.89M
Basic EPS	$-1.53	$-4.43	$0.73
Diluted EPS	$-1.53	$-4.43	$0.70

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 07, 26 | 12:00 AM

Q4 25Mar 03, 26 | 8:00 AM

Q3 25Nov 06, 25 | 8:00 AM

Peer Comparison

Ticker	Company
IMTX	Immatics N.V.
ATAI	Atai Beckley Inc.
RLAY	Relay Therapeutics, Inc.
NKTR	Nektar Therapeutics
CVAC	CureVac N.V.
SANA	Sana Biotechnology, Inc.
SNDX	Syndax Pharmaceuticals, Inc.
ORIC	ORIC Pharmaceuticals, Inc.
PGEN	Precigen, Inc.
INBX	Inhibrx Biosciences, Inc.